Effects of Intranasal Nerve Growth Factor for Traumatic Brain Injury
Traumatic bain injury(TBI) remains a hidden epidemic involving individuals affected predominantly at a young age who in the most severe cases remain with permanent physical,psychological and cognitive deficits.This study will investigate the therapeutic effects of intranasal Nerve Growth Factor(NGF) in TBI.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Pilot Study of Intranasal Nerve Growth Factor for Traumatic Brain Injury(TBI)|
- improved neurological functions [ Time Frame: at months 6 post-treatment ] [ Designated as safety issue: Yes ]Neurological functions will be assessed by GOS(Glasgow Outcome Scale), mRS(modified Rankin Scale),BI(Barthel index).
- HAMA,HAMD [ Time Frame: at months 6 post-treatment ] [ Designated as safety issue: Yes ]HAMA(Hamilton Anxiety Scale ),HAMD(Hamilton Depression Scale).
|Study Start Date:||December 2010|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Experimental: nerve growth factor
Patients who underwent TBI will be chosen to receive NGF randomly. Experimental:nomral saline group Patients who underwent TBI will be chosen to receive nomral saline randomly.
Drug: nerve growth factor
The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
Other Name: GM1
Early NGF concentration in the cerebral spinal fluid(CSF)correlates significantly with the severity of head injury, and NGF upregulation correlates with better neurologic outcomes and could be useful to obtain clinical and prognostic information in patients with serve TBI.
However, the clinical use of NGF is difficulty associated with delivering them to the CNS because of the existing of blood-brain barrier(BBB). Intranasal delivery drug is a noninvasive and convenient novel method bypassing BBB, which results in targeting therapeutics to the CNS rapidly.
The proposed study is a randomized, double-blind, placebo-controlled trail of NGF, starting between 24 to 72 hours post TBI, continuing for 2 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01212679
|Contact: Xinfeng Liu, MDemail@example.com|
|Department of Neurology, Jinling Hospital, Nanjing University School of Medicine||Recruiting|
|Nanjing, Jiangsu, China, 210002|
|Contact: Xinfeng Liu, MD 86-25-84801861 firstname.lastname@example.org|
|Principal Investigator: Xinfeng Liu, MD|
|Study Chair:||Xinfeng Liu, MD||Department of Neurology, Jinling Hospital, Nanjing University School of Medicine|